Jennifer Doudna Sells 2,673 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 2,673 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $147,015.00. Following the completion of the transaction, the director directly owned 25,942 shares of the company’s stock, valued at approximately $1,426,810. This trade represents a 9.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Up 6.3%

Shares of NASDAQ:TEM opened at $61.60 on Thursday. The company’s 50-day moving average price is $50.28 and its two-hundred day moving average price is $54.60. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The stock has a market capitalization of $11.06 billion, a PE ratio of -35.81 and a beta of 3.45.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.24) EPS. On average, equities analysts forecast that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. GC Wealth Management RIA LLC bought a new position in shares of Tempus AI during the 4th quarter worth approximately $399,267,000. Voloridge Investment Management LLC lifted its holdings in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after purchasing an additional 965,730 shares during the last quarter. AQR Capital Management LLC bought a new position in Tempus AI during the second quarter worth $54,020,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the period. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research report on Monday, June 1st. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Monday, June 1st. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Jefferies Financial Group began coverage on shares of Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Finally, HC Wainwright dropped their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.54.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.